JPWO2021050864A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021050864A5 JPWO2021050864A5 JP2022515906A JP2022515906A JPWO2021050864A5 JP WO2021050864 A5 JPWO2021050864 A5 JP WO2021050864A5 JP 2022515906 A JP2022515906 A JP 2022515906A JP 2022515906 A JP2022515906 A JP 2022515906A JP WO2021050864 A5 JPWO2021050864 A5 JP WO2021050864A5
- Authority
- JP
- Japan
- Prior art keywords
- hcmv
- sequence
- seq
- immunogenic composition
- mrna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 42
- 241000701024 Human betaherpesvirus 5 Species 0.000 claims 39
- 230000002163 immunogen Effects 0.000 claims 35
- 229920001184 polypeptide Polymers 0.000 claims 21
- 102000004196 processed proteins & peptides Human genes 0.000 claims 21
- 108090000765 processed proteins & peptides Proteins 0.000 claims 21
- 108700026244 Open Reading Frames Proteins 0.000 claims 20
- 239000002773 nucleotide Substances 0.000 claims 19
- 125000003729 nucleotide group Chemical group 0.000 claims 19
- 208000015181 infectious disease Diseases 0.000 claims 10
- 230000003472 neutralizing effect Effects 0.000 claims 10
- 108090000623 proteins and genes Proteins 0.000 claims 10
- 102000004169 proteins and genes Human genes 0.000 claims 10
- 150000002632 lipids Chemical class 0.000 claims 9
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 8
- 210000002919 epithelial cell Anatomy 0.000 claims 8
- 101100315698 Human cytomegalovirus (strain Merlin) UL131A gene Proteins 0.000 claims 7
- 239000002105 nanoparticle Substances 0.000 claims 6
- 239000002157 polynucleotide Substances 0.000 claims 6
- 102000040430 polynucleotide Human genes 0.000 claims 6
- 108091033319 polynucleotide Proteins 0.000 claims 6
- -1 cationic lipid Chemical class 0.000 claims 5
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 claims 4
- 235000012000 cholesterol Nutrition 0.000 claims 4
- 229960005486 vaccine Drugs 0.000 claims 4
- 238000000034 method Methods 0.000 claims 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 2
- 101900039244 Human cytomegalovirus Envelope glycoprotein UL130 Proteins 0.000 claims 2
- 101900003124 Human cytomegalovirus Envelope protein UL128 Proteins 0.000 claims 2
- 238000010255 intramuscular injection Methods 0.000 claims 2
- 239000007927 intramuscular injection Substances 0.000 claims 2
- JFBCSFJKETUREV-LJAQVGFWSA-N 1,2-ditetradecanoyl-sn-glycerol Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](CO)OC(=O)CCCCCCCCCCCCC JFBCSFJKETUREV-LJAQVGFWSA-N 0.000 claims 1
- UVBYMVOUBXYSFV-XUTVFYLZSA-N 1-methylpseudouridine Chemical compound O=C1NC(=O)N(C)C=C1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 UVBYMVOUBXYSFV-XUTVFYLZSA-N 0.000 claims 1
- UVBYMVOUBXYSFV-UHFFFAOYSA-N 1-methylpseudouridine Natural products O=C1NC(=O)N(C)C=C1C1C(O)C(O)C(CO)O1 UVBYMVOUBXYSFV-UHFFFAOYSA-N 0.000 claims 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 238000007385 chemical modification Methods 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 210000002950 fibroblast Anatomy 0.000 claims 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 229920002477 rna polymer Polymers 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 230000001568 sexual effect Effects 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962899129P | 2019-09-11 | 2019-09-11 | |
| US62/899,129 | 2019-09-11 | ||
| US201962899624P | 2019-09-12 | 2019-09-12 | |
| US62/899,624 | 2019-09-12 | ||
| US202062958623P | 2020-01-08 | 2020-01-08 | |
| US62/958,623 | 2020-01-08 | ||
| PCT/US2020/050392 WO2021050864A1 (en) | 2019-09-11 | 2020-09-11 | Human cytomegalovirus vaccine |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022547313A JP2022547313A (ja) | 2022-11-11 |
| JP2022547313A5 JP2022547313A5 (https=) | 2023-09-20 |
| JPWO2021050864A5 true JPWO2021050864A5 (https=) | 2023-09-20 |
Family
ID=74867306
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022515906A Withdrawn JP2022547313A (ja) | 2019-09-11 | 2020-09-11 | ヒトサイトメガロウイルスワクチン |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20220347292A1 (https=) |
| EP (1) | EP4028030A4 (https=) |
| JP (1) | JP2022547313A (https=) |
| AU (1) | AU2020346041A1 (https=) |
| CA (1) | CA3154082A1 (https=) |
| WO (1) | WO2021050864A1 (https=) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201912038TA (en) | 2014-04-23 | 2020-02-27 | Modernatx Inc | Nucleic acid vaccines |
| US11364292B2 (en) | 2015-07-21 | 2022-06-21 | Modernatx, Inc. | CHIKV RNA vaccines |
| WO2017020026A1 (en) | 2015-07-30 | 2017-02-02 | Modernatx, Inc. | Concatemeric peptide epitopes rnas |
| WO2017031232A1 (en) | 2015-08-17 | 2017-02-23 | Modernatx, Inc. | Methods for preparing particles and related compositions |
| CA3002912A1 (en) | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Nucleic acid vaccines for varicella zoster virus (vzv) |
| EP3364981A4 (en) | 2015-10-22 | 2019-08-07 | ModernaTX, Inc. | VACCINE AGAINST THE HUMAN CYTOMEGALOVIRUS |
| EP3364950A4 (en) | 2015-10-22 | 2019-10-23 | ModernaTX, Inc. | VACCINES AGAINST TROPICAL DISEASES |
| TW201729835A (zh) | 2015-10-22 | 2017-09-01 | 現代公司 | 呼吸道病毒疫苗 |
| EP3364949A4 (en) | 2015-10-22 | 2019-07-31 | ModernaTX, Inc. | CANCER VACCINES |
| HRP20220652T1 (hr) | 2015-12-10 | 2022-06-24 | Modernatx, Inc. | Pripravci i postupci unosa terapijskih sredstava |
| MA45052A (fr) | 2016-05-18 | 2019-03-27 | Modernatx Inc | Polynucléotides codant pour jagged1 pour le traitement du syndrome d'alagille |
| CN116837052A (zh) | 2016-09-14 | 2023-10-03 | 摩登纳特斯有限公司 | 高纯度rna组合物及其制备方法 |
| MA46584A (fr) | 2016-10-21 | 2019-08-28 | Modernatx Inc | Vaccin contre le cytomégalovirus humain |
| WO2018089851A2 (en) | 2016-11-11 | 2018-05-17 | Modernatx, Inc. | Influenza vaccine |
| WO2018111967A1 (en) | 2016-12-13 | 2018-06-21 | Modernatx, Inc. | Rna affinity purification |
| EP3595713A4 (en) | 2017-03-15 | 2021-01-13 | ModernaTX, Inc. | RESPIRATORY SYNCYTIAL VIRUS Vaccine |
| US11752206B2 (en) | 2017-03-15 | 2023-09-12 | Modernatx, Inc. | Herpes simplex virus vaccine |
| WO2018170245A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Broad spectrum influenza virus vaccine |
| US11045540B2 (en) | 2017-03-15 | 2021-06-29 | Modernatx, Inc. | Varicella zoster virus (VZV) vaccine |
| MA47790A (fr) | 2017-03-17 | 2021-05-05 | Modernatx Inc | Vaccins à base d'arn contre des maladies zoonotiques |
| WO2018187590A1 (en) | 2017-04-05 | 2018-10-11 | Modernatx, Inc. | Reduction or elimination of immune responses to non-intravenous, e.g., subcutaneously administered therapeutic proteins |
| US11786607B2 (en) | 2017-06-15 | 2023-10-17 | Modernatx, Inc. | RNA formulations |
| ES2983060T3 (es) | 2017-08-18 | 2024-10-21 | Modernatx Inc | Variantes de ARN polimerasa |
| WO2019036685A1 (en) | 2017-08-18 | 2019-02-21 | Modernatx, Inc. | METHODS FOR HPLC ANALYSIS |
| WO2019036683A1 (en) | 2017-08-18 | 2019-02-21 | Modernatx, Inc. | ANALYTICAL METHODS BY HPLC |
| WO2019046809A1 (en) | 2017-08-31 | 2019-03-07 | Modernatx, Inc. | METHODS OF MANUFACTURING LIPID NANOPARTICLES |
| EP3681514A4 (en) | 2017-09-14 | 2021-07-14 | ModernaTX, Inc. | RNA VACZINE AGAINST ZIKA VIRUS |
| WO2019148101A1 (en) | 2018-01-29 | 2019-08-01 | Modernatx, Inc. | Rsv rna vaccines |
| MA53650A (fr) | 2018-09-19 | 2021-07-28 | Modernatx Inc | Lipides peg et leurs utilisations |
| AU2019345067A1 (en) | 2018-09-19 | 2021-04-08 | Modernatx, Inc. | High-purity peg lipids and uses thereof |
| CN113271926A (zh) | 2018-09-20 | 2021-08-17 | 摩登纳特斯有限公司 | 脂质纳米颗粒的制备及其施用方法 |
| CN113795579A (zh) | 2019-02-20 | 2021-12-14 | 摩登纳特斯有限公司 | 用于共转录加帽的rna聚合酶变体 |
| US11851694B1 (en) | 2019-02-20 | 2023-12-26 | Modernatx, Inc. | High fidelity in vitro transcription |
| CA3132975A1 (en) | 2019-03-11 | 2020-09-17 | Modernatx, Inc. | Fed-batch in vitro transcription process |
| EP3938379A4 (en) | 2019-03-15 | 2023-02-22 | ModernaTX, Inc. | Hiv rna vaccines |
| EP3901261A1 (en) | 2020-04-22 | 2021-10-27 | BioNTech RNA Pharmaceuticals GmbH | Coronavirus vaccine |
| MX2023002377A (es) * | 2020-08-25 | 2023-05-22 | Modernatx Inc | Vacuna contra el citomegalovirus humano. |
| US11406703B2 (en) | 2020-08-25 | 2022-08-09 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| US12329811B2 (en) | 2021-01-11 | 2025-06-17 | Modernatx, Inc. | Seasonal RNA influenza virus vaccines |
| US20220363937A1 (en) | 2021-05-14 | 2022-11-17 | Armstrong World Industries, Inc. | Stabilization of antimicrobial coatings |
| CN115611757A (zh) * | 2021-07-16 | 2023-01-17 | 江苏慧聚药业股份有限公司 | mRNA传递剂的合成 |
| CN115703713B (zh) * | 2021-08-13 | 2025-06-10 | 广州谷森制药有限公司 | 阳离子脂质化合物 |
| US12186387B2 (en) | 2021-11-29 | 2025-01-07 | BioNTech SE | Coronavirus vaccine |
| US12529047B1 (en) | 2021-12-21 | 2026-01-20 | Modernatx, Inc. | mRNA quantification methods |
| WO2023212696A1 (en) | 2022-04-29 | 2023-11-02 | Modernatx, Inc. | Lyophilized human cytomegalovirus vaccines |
| WO2024002985A1 (en) | 2022-06-26 | 2024-01-04 | BioNTech SE | Coronavirus vaccine |
| CN115948468A (zh) * | 2022-09-09 | 2023-04-11 | 青岛大学 | 一种人巨细胞病毒重组载体及其制备方法和应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3364981A4 (en) * | 2015-10-22 | 2019-08-07 | ModernaTX, Inc. | VACCINE AGAINST THE HUMAN CYTOMEGALOVIRUS |
| MA46584A (fr) * | 2016-10-21 | 2019-08-28 | Modernatx Inc | Vaccin contre le cytomégalovirus humain |
-
2020
- 2020-09-11 CA CA3154082A patent/CA3154082A1/en active Pending
- 2020-09-11 WO PCT/US2020/050392 patent/WO2021050864A1/en not_active Ceased
- 2020-09-11 EP EP20863988.0A patent/EP4028030A4/en not_active Withdrawn
- 2020-09-11 JP JP2022515906A patent/JP2022547313A/ja not_active Withdrawn
- 2020-09-11 US US17/641,967 patent/US20220347292A1/en not_active Abandoned
- 2020-09-11 AU AU2020346041A patent/AU2020346041A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2021050864A5 (https=) | ||
| CN114081943B (zh) | 一种水痘-带状疱疹mRNA疫苗组合物及其制备方法和应用 | |
| Donnelly et al. | Protection against papillomavirus with a polynucleotide vaccine | |
| JP3530526B2 (ja) | ＨＳＶ糖蛋白質ｇＤおよび３脱アシル化モノホスホリルリピッドＡからなる単純ヘルペスワクチン | |
| AU2003218787B2 (en) | Virus-like particles of human papillomavirus | |
| JP2019535665A5 (https=) | ||
| JP2002508333A (ja) | ワクチン | |
| JP2024538768A (ja) | Ｒｎａ分子 | |
| CN110996999A (zh) | 包含插入有脂肽的脂质体作为有效成分的疫苗佐剂及其用途 | |
| CN116655748B (zh) | 一种截短型水痘-带状疱疹病毒gE蛋白及其应用 | |
| US20250000968A1 (en) | Sars-cov-2 spike fused to a hepatitis b surface antigen | |
| CZ20014392A3 (cs) | Vakcína AND pro domácí a sportovní zvířata | |
| CN115820696A (zh) | 治疗性多价HPV mRNA疫苗及其制备方法 | |
| CN114277039B (zh) | 呼吸道合胞病毒mRNA疫苗及其制备方法和应用 | |
| WO2024041612A1 (zh) | 一种正痘病毒属mRNA疫苗及其制备方法和用途 | |
| KR20140045341A (ko) | Siv/hiv로부터의 보호를 위한 조합된 세포 기반의 gp96-ig-siv/hiv, 재조합 gp120 단백질 백신접종 | |
| JP2010180253A (ja) | 抗原または免疫原に対する免疫応答を仕立てる方法。 | |
| CN120305396A (zh) | 一种猴痘病毒抗原表位mRNA组合物及其应用 | |
| CN120888568A (zh) | 一种预防或治疗乙肝病毒感染的mRNA疫苗及其应用 | |
| CN117126253B (zh) | Hsv免疫原性重组蛋白、其制备方法和应用、以及用其制备的疫苗 | |
| JP2024151316A (ja) | Ｒｎａ分子 | |
| WO2024114650A1 (zh) | 一种重组带状疱疹疫苗及其制备与应用 | |
| CN117618548A (zh) | 一种rsv疫苗组合物及其制备方法和应用 | |
| JPH09509415A (ja) | ワクチンアジュバントとしてのプロラクチン | |
| JP4535874B2 (ja) | 肝炎に対するバクテリオファージを介する免疫 |